» Articles » PMID: 22554352

Body Composition in Patients with Schizophrenia: Comparison with Healthy Controls

Overview
Publisher Biomed Central
Specialty Psychiatry
Date 2012 May 5
PMID 22554352
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled:

Background: Recently, a relationship between obesity and schizophrenia has been reported. Although fat- mass and fat free mass have been shown to be more predictive of health risk than body mass index, there are limited findings about body composition among patients suffering from schizophrenia. The aim of this study is to compare the body composition of schizophrenia patients with that of healthy subjects in Japan.

Methods: We recruited patients (n = 204), aged 41.3 ± 13.8 (mean ± SD) years old with the DSM-IV diagnosis of schizophrenia who were admitted to psychiatric hospital using a cross-sectional design. Subjects' anthropometric measurements including weight, height, body mass index (BMI), and medications were also collected. Body fat, percent (%) body fat, fat- free mass, muscle mass, and body water were measured using the bioelectrical impedance analysis (BIA) method. Comparative analysis was performed with schizophrenic subjects and 204 healthy control individuals.

Results: In a multiple regression model with age, body mass index, and dose in chlorpromazine equivalents, schizophrenia was a significantly linked with more body fat, higher % body fat, lower fat- free mass, lower muscle mass, and lower body water among males. In females, schizophrenia had a significant association with lower % body fat, higher fat- free mass, higher muscle mass, and higher body water.

Conclusions: Our data demonstrate gender differences with regard to changes in body composition in association with schizophrenia. These results indicate that intervention programs designed to fight obesity among schizophrenic patients should be individualized according to gender.

Citing Articles

Adherence to Dietary Recommendations in Organized Living Beneficiaries with Severe Mental Disorders and Their Caregivers.

Soher L, Cvijetic Stokanovic M, Prsa S, Miskulin M, Kenjeric D Nutrients. 2024; 16(1).

PMID: 38201972 PMC: 10780574. DOI: 10.3390/nu16010143.


Examining Factors Associated with Dynapenia/Sarcopenia in Patients with Schizophrenia: A Pilot Case-Control Study.

Tanioka R, Osaka K, Ito H, Zhao Y, Tomotake M, Takase K Healthcare (Basel). 2023; 11(5).

PMID: 36900689 PMC: 10000555. DOI: 10.3390/healthcare11050684.


Investigating Body Mass Index and Body Composition in Patients with Schizophrenia: A Case-Control Study.

Marthoenis M, Martina M, Alfiandi R, Dahniar D, Asnurianti R, Sari H Schizophr Res Treatment. 2022; 2022:1381542.

PMID: 35265376 PMC: 8898882. DOI: 10.1155/2022/1381542.


Predictive Utility of Body Mass Index for Metabolic Syndrome Among Patients with Schizophrenia in Japan.

Sugawara N, Yasui-Furukori N, Yamazaki M, Shimoda K, Mori T, Sugai T Neuropsychiatr Dis Treat. 2020; 16:2229-2236.

PMID: 33061393 PMC: 7533264. DOI: 10.2147/NDT.S269619.


The Role of Genetic Variation of BMI, Body Composition, and Fat Distribution for Mental Traits and Disorders: A Look-Up and Mendelian Randomization Study.

Peters T, Nullig L, Antel J, Naaresh R, Laabs B, Tegeler L Front Genet. 2020; 11:373.

PMID: 32373164 PMC: 7186862. DOI: 10.3389/fgene.2020.00373.


References
1.
Tiidus P . Estrogen and gender effects on muscle damage, inflammation, and oxidative stress. Can J Appl Physiol. 2000; 25(4):274-87. DOI: 10.1139/h00-022. View

2.
Boneva-Asiova Z, Boyanov M . Body composition analysis by leg-to-leg bioelectrical impedance and dual-energy X-ray absorptiometry in non-obese and obese individuals. Diabetes Obes Metab. 2008; 10(11):1012-8. DOI: 10.1111/j.1463-1326.2008.00851.x. View

3.
Ellis K . Human body composition: in vivo methods. Physiol Rev. 2000; 80(2):649-80. DOI: 10.1152/physrev.2000.80.2.649. View

4.
Roubenoff R . Sarcopenia: effects on body composition and function. J Gerontol A Biol Sci Med Sci. 2003; 58(11):1012-7. DOI: 10.1093/gerona/58.11.m1012. View

5.
Correll C, Manu P, Olshanskiy V, Napolitano B, Kane J, Malhotra A . Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009; 302(16):1765-73. PMC: 3055794. DOI: 10.1001/jama.2009.1549. View